MYOK News and Press, MyoKardia Inc. From 09/10/19

SOUTH SAN FRANCISCO, Calif., Sept. 10, 2019 (GLOBE NEWSWIRE) -- MyoKardia, Inc. (Nasdaq: MYOK), today announced that it will study mavacamten as a therapeutic alternative to septal reduction therapy (SRT). The study will be conducted at leading HCM centers that regularly perform surgical my...

Results from an open-label extension study from the Phase 2 PIONEER-HCM trial evaluating MyoKardia's ( MYOK -0.2% ) mavacamten in patients with symptomatic obstructive hypertrophic cardiomyopathy (HCM) showed a durable treatment effect through week 36. The data were presented at the ES...

Durability of Mavacamten's Safety and Efficacy Profile Demonstrated through Nine Months in this Study of Patients with Symptomatic, Obstructive HCM Statistically Significant Changes in Key Biomarkers Maintained, Indicative of Potential Improvements in Cardiac Function and Fav...

SOUTH SAN FRANCISCO, Calif., Aug. 28, 2019 (GLOBE NEWSWIRE) -- MyoKardia, Inc. (Nasdaq: MYOK), today announced its participation in the following upcoming investor conferences: Citi 14 th Annual Biotech Conference in Boston, MA on Wednesday, September 4, 2019. 2019 Wells Fargo Heal...

SOUTH SAN FRANCISCO, Calif., Aug. 26, 2019 (GLOBE NEWSWIRE) -- MyoKardia, Inc. (Nasdaq: MYOK) today announced the presentation of three abstracts at the upcoming European Society of Cardiology (ESC) Congress taking place August 31 – September 4, 2019 in Paris, France. Among the highl...

The first participants have been dosed in a Phase 1 clinical trial evaluating MyoKardia's ( MYOK +0.5% ) MYK-224 for the treatment of hypertrophic cardiomyopathy  (HCM), a common heart condition in which the cardiac muscle cells enlarge causing the walls of the ventricles to thicke...

SOUTH SAN FRANCISCO, Calif., Aug. 21, 2019 (GLOBE NEWSWIRE) -- MyoKardia, Inc. (Nasdaq: MYOK) today announced that it has dosed the first subjects in a Phase 1 clinical study of MYK-224, a small molecule candidate being developed for the treatment of hypertrophic cardiomyopathy (HCM). ...

SOUTH SAN FRANCISCO, Calif., Aug. 15, 2019 (GLOBE NEWSWIRE) -- MyoKardia, Inc. today announced the launch of the 2 nd Annual MyoSeeds ™ Research Grants Program, an initiative to support original, independent research in the biology and underlying mechanisms of cardiomyopathies and ...

MyoKardia (MYOK) Q2 2019 Earnings Conference Call August 7, 2019 16:30 ET Company Participants Michelle Corral - Investor Relations Tassos Gianakakos - Chief Executive Officer Jay Edelberg - Senior Vice President, Clinical Development Taylor Harris - Chief Financial Officer J...

MyoKardia (NASDAQ: MYOK ): Q2 GAAP EPS of -$0.83 beats by $0.17 . More news on: MyoKardia, Inc., Earnings news and commentary, Healthcare stocks news, Read more ...